Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(2 years from now) | |
US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(3 years from now) | |
US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
New Indication (I) | Aug 10, 2024 |
M | Dec 19, 2024 |
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic